ClinicalTrials.Veeva

Menu

Acute Myeloid Leukemia Registry (AMLREGISTRY)

T

Turkish Hematology Association

Status

Enrolling

Conditions

Acute Myeloid Leukemia

Study type

Observational

Funder types

Other

Identifiers

NCT05979675
AML_Registry

Details and patient eligibility

About

All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

Full description

This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.

Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.

All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.

Enrollment

250 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed as AML after 1 Jan 2020
  • Patients signed informed consent form

Exclusion criteria

  • Patients under 18 years old

Trial contacts and locations

1

Loading...

Central trial contact

Volkan Karakus, Assoc. Prof.; Ilker Kurkcu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems